MedWatch

The canadian market potential is 10 million doses

Even though the initial number of small pox vaccines bought by the Canadian government is relatively small the potential is great – and Europe could be right around the corner.

Canada has just bought 20,000 doses of Bavarian Nordic’s vaccine with an option to buy an additional 180,000, but the market potential for the country is 10 million doses, Bavarian CEO Anders Hedegaard tells Medwatch. Meanwhile, the company has begun negotiations with a number of other countries, and they hope to start delivering the vaccine to European countries in the near future.

“There is a lot of money in this order. But there is also a positive signal value, in that they place the order prior to approval. To us that means they view Imvamune in a positive light, although there are no guarantees,” he points out and adds:

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

KU søger chef til nyt life science-program

Københavns Universitet har indledt jagten på den programdirektør, der skal stå i spidsen for innovationsprogrammet Spark Denmark, som Novo Nordisk Fonden forleden kastede 44 mio. kr. efter for at bringe flere akademiske projekter indenfor farma, medico, sundhedsteknologi og industriel biotek til markedet.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier